95 related articles for article (PubMed ID: 18555479)
1. Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.
Kountourakis P; Kandylis K; Daskalopoulou D; Rigatos G
J BUON; 2008; 13(2):281-3. PubMed ID: 18555479
[TBL] [Abstract][Full Text] [Related]
2. [Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].
Tsuchiyama K; Ito H; Ishida H; Itoh H; Yokoyama O
Hinyokika Kiyo; 2011 Nov; 57(11):615-8. PubMed ID: 22166824
[TBL] [Abstract][Full Text] [Related]
3. Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.
Kunene V; Miscoria M; Pirrie S; Islam MR; Afshar M; Porfiri E
Clin Genitourin Cancer; 2014 Aug; 12(4):251-5. PubMed ID: 24560086
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for sarcomatoid renal cell carcinoma.
Pagliaro LC; Tannir N; Sircar K; Jonasch E
Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
[TBL] [Abstract][Full Text] [Related]
5. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
6. Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.
Messina C; Di Meglio A; Nuzzo PV; Boccardo F; Ricci F
Tumori; 2015; 101(3):e79-81. PubMed ID: 26045116
[TBL] [Abstract][Full Text] [Related]
7. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
8. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
[No Abstract] [Full Text] [Related]
9. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Heng DY; Rini BI; Garcia J; Wood L; Bukowski RM
Clin Genitourin Cancer; 2007 Dec; 5(7):446-51. PubMed ID: 18272027
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus for advanced renal-cell carcinoma.
Fazio N; Dettori M; Lorizzo K
N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17804854
[No Abstract] [Full Text] [Related]
11. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
12. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Neill MG; Wei AC; Jewett MA
Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
[TBL] [Abstract][Full Text] [Related]
13. The nasal septum: an unusual presentation of metastatic renal cell carcinoma.
Doğan S; Can IH; Sayn M; Ozer E; Bayz U; Yazici G; Samim EE
J Craniofac Surg; 2009 Jul; 20(4):1204-6. PubMed ID: 19553840
[TBL] [Abstract][Full Text] [Related]
14. [Three cases of renal cell carcinoma with sarcomatoid differentiation].
Di Primio OG; Manini C; Vella R; Pedalino M; Piras D; Vercesi E; Marino G
Urologia; 2010; 77 Suppl 17():42-5. PubMed ID: 21308674
[TBL] [Abstract][Full Text] [Related]
15. Brain metastases in patients with renal cell cancer receiving new targeted treatment.
Helgason HH; Mallo HA; Droogendijk H; Haanen JG; van der Veldt AA; van den Eertwegh AJ; Boven E
J Clin Oncol; 2008 Jan; 26(1):152-4. PubMed ID: 18165649
[No Abstract] [Full Text] [Related]
16. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Michaelson MD; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
Cancer; 2015 Oct; 121(19):3435-43. PubMed ID: 26058385
[TBL] [Abstract][Full Text] [Related]
18. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
Bangalore N; Bhargava P; Hawkins MJ; Bhargava P
Ann Oncol; 2001 Feb; 12(2):271-4. PubMed ID: 11300337
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid chromophobe renal cell carcinoma: A rare entity with prognostic significance.
Sharma R; Kaushal V
J Cancer Res Ther; 2015; 11(4):1030. PubMed ID: 26881614
[TBL] [Abstract][Full Text] [Related]
20. Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma.
Rouvinov K; Osyntsov L; Shaco-Levy R; Baram N; Ariad S; Mermershtain W
Clin Genitourin Cancer; 2017 Dec; 15(6):e1127-e1130. PubMed ID: 28673798
[No Abstract] [Full Text] [Related]
[Next] [New Search]
